Radical Reform Plan For Health Care In Japan

10 August 1997

If the new reform plan announced by Japan's Ministry of Health & Welfareon August 7 is approved by the government, a major change in drug pricing will take place in that country.

The government now sets fixed reimbursement prices for drugs under the present health insurance system which encourages hospitals and doctors to negotiate a lower price from suppliers to generate a margin for themselves. In short, the current practice encourages hospitals and doctors to provide more service and drugs to their patients because this results in more reimbursement by the health insurance system, thus contributing to Japan's rising health insurance deficit.

German-Style Reference Price System Proposed The proposed reform will abolish the present reimbursement system. Instead, drug manufacturers and wholesalers will be allowed to freely set their own prices. However, in return, the government will set reference prices for reimbursement, rather along the lines of the German system, according to a Ministry official.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight